MX9705296A - Novel compounds. - Google Patents
Novel compounds.Info
- Publication number
- MX9705296A MX9705296A MX9705296A MX9705296A MX9705296A MX 9705296 A MX9705296 A MX 9705296A MX 9705296 A MX9705296 A MX 9705296A MX 9705296 A MX9705296 A MX 9705296A MX 9705296 A MX9705296 A MX 9705296A
- Authority
- MX
- Mexico
- Prior art keywords
- novel compounds
- cycloalkyl
- therapy
- preparation
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
This invention relates to 1-cycloalkyl, 4,5-trisubstituted imidazole compounds, process for the preparation thereof, the use thereof in treating cytokine mediated diseases and pharmaceutical compositions for the use in such therapy.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37252195A | 1995-01-12 | 1995-01-12 | |
US37427895A | 1995-01-18 | 1995-01-18 | |
US48334895A | 1995-06-07 | 1995-06-07 | |
PCT/US1996/001094 WO1996021654A1 (en) | 1995-01-12 | 1996-01-11 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9705296A true MX9705296A (en) | 1997-10-31 |
Family
ID=27409084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9705296A MX9705296A (en) | 1995-01-12 | 1996-01-11 | Novel compounds. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0802908A4 (en) |
JP (1) | JPH10512264A (en) |
KR (1) | KR19980701374A (en) |
AU (1) | AU709370B2 (en) |
BR (1) | BR9607097A (en) |
CA (1) | CA2210322A1 (en) |
CZ (1) | CZ219597A3 (en) |
FI (1) | FI972970A (en) |
HU (1) | HUP0102677A3 (en) |
MX (1) | MX9705296A (en) |
NO (1) | NO973231L (en) |
NZ (1) | NZ302117A (en) |
PL (1) | PL321292A1 (en) |
WO (1) | WO1996021654A1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US6369068B1 (en) | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
ZA9610687B (en) * | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
NZ327044A (en) * | 1996-01-11 | 2000-01-28 | Smithkline Beecham Corp | Substituted imidazole compounds |
JP2001508395A (en) * | 1996-01-11 | 2001-06-26 | スミスクライン・ビーチャム・コーポレイション | New cycloalkyl-substituted imidazole |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
AP9700912A0 (en) * | 1996-01-11 | 1997-01-31 | Smithkline Beecham Corp | Novel cycloalkyl substituted imidazoles |
US6096748A (en) * | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
WO1997035856A1 (en) * | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5939069A (en) | 1996-08-23 | 1999-08-17 | University Of Florida | Materials and methods for detection and treatment of immune system dysfunctions |
PT948495E (en) | 1996-11-19 | 2004-08-31 | Amgen Inc | ANTI-INFLAMMATORY AGENTS OF FUSED PYRROLE SUBSTITUTED IN ARYL AND HETEROARYL |
CA2271893A1 (en) * | 1996-11-20 | 1998-05-28 | Linda L. Chang | Triaryl substituted imidazoles as glucagon antagonists |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
ZA9711092B (en) * | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6608060B1 (en) | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5929076A (en) * | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
WO1998056377A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
CA2294137A1 (en) | 1997-06-19 | 1998-12-23 | Smithkline Beecham Corporation | Novel aryloxy substituted pyrimidine imidazole compounds |
AR016294A1 (en) * | 1997-07-02 | 2001-07-04 | Smithkline Beecham Corp | IMIDAZOL SUBSTITUTE COMPOSITE, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR SUPREPARATION |
US6489325B1 (en) | 1998-07-01 | 2002-12-03 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6562832B1 (en) | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
EP1019396A1 (en) | 1997-07-02 | 2000-07-19 | SmithKline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
EP1041989A4 (en) * | 1997-10-08 | 2002-11-20 | Smithkline Beecham Corp | Novel cycloalkenyl substituted compounds |
AU9449398A (en) * | 1997-10-10 | 1999-05-03 | Imperial College Innovations Ltd. | Use of csaidtm compounds for the management of uterine contractions |
EP1473292A1 (en) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
WO1999023091A1 (en) * | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
CA2314980A1 (en) | 1997-12-19 | 1999-07-01 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
KR20010025087A (en) | 1998-05-22 | 2001-03-26 | 스튜어트 알. 수터 | Novel 2-Alkyl Substituted Imidazole Compounds |
US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6207687B1 (en) * | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
US6599910B1 (en) | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
ATE258055T1 (en) | 1998-11-04 | 2004-02-15 | Smithkline Beecham Corp | PYRIDINE-4-YL OR PYRIMIDINE-4-YL SUBSTITUTED PYRAZINE |
US6239279B1 (en) | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
DE60023025T2 (en) | 1999-11-23 | 2006-07-13 | Smithkline Beecham Corp. | 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS |
EP1233951B1 (en) | 1999-11-23 | 2005-06-01 | SmithKline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
WO2002100405A1 (en) | 2001-06-11 | 2002-12-19 | Vertex Pharmaceuticals Incorporated | Isoquinoline inhibitors of p38 |
TWI329642B (en) * | 2001-10-22 | 2010-09-01 | Mitsubishi Tanabe Pharma Corp | 4-imidazolin-2-one compounds |
WO2004019873A2 (en) | 2002-08-29 | 2004-03-11 | Scios Inc. | Methods of promoting osteogenesis |
MXPA05008450A (en) | 2003-02-10 | 2005-10-18 | Vertex Pharma | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes. |
CA2535980A1 (en) * | 2003-06-06 | 2005-01-06 | The Trustees Of The University Of Pennsylvania | P38 kinase inhibitor compositions and methods of use |
WO2010093889A2 (en) | 2009-02-13 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide |
EP2396302A2 (en) | 2009-02-13 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) |
EP3273955A4 (en) * | 2015-03-23 | 2019-05-01 | The University of Melbourne | Treatment of respiratory diseases |
JP2016193861A (en) * | 2015-03-31 | 2016-11-17 | 国立大学法人山梨大学 | Pharmaceutical compositions for inhibiting mast cell activation |
ES2908041T3 (en) | 2015-10-27 | 2022-04-27 | Childrens Hospital Med Ct | Use of MAPK inhibitors to reduce hematopoietic stem cell loss during ex vivo culture and genetic manipulation |
CN113260616A (en) * | 2018-11-07 | 2021-08-13 | 墨尔本大学 | Novel compounds for the treatment of respiratory diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
JPH0819110B2 (en) * | 1986-06-04 | 1996-02-28 | 富山化学工業株式会社 | Novel imidazole derivative or salt thereof and anti-inflammatory agent, antipyretic analgesic agent or anti-arthritic agent containing them |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
-
1996
- 1996-01-11 AU AU47704/96A patent/AU709370B2/en not_active Ceased
- 1996-01-11 NZ NZ302117A patent/NZ302117A/en unknown
- 1996-01-11 JP JP8521882A patent/JPH10512264A/en active Pending
- 1996-01-11 HU HU0102677A patent/HUP0102677A3/en unknown
- 1996-01-11 CZ CZ972195A patent/CZ219597A3/en unknown
- 1996-01-11 BR BR9607097A patent/BR9607097A/en not_active Application Discontinuation
- 1996-01-11 KR KR1019970704763A patent/KR19980701374A/en not_active Application Discontinuation
- 1996-01-11 MX MX9705296A patent/MX9705296A/en unknown
- 1996-01-11 CA CA002210322A patent/CA2210322A1/en not_active Abandoned
- 1996-01-11 WO PCT/US1996/001094 patent/WO1996021654A1/en not_active Application Discontinuation
- 1996-01-11 EP EP96903709A patent/EP0802908A4/en not_active Withdrawn
- 1996-01-11 PL PL96321292A patent/PL321292A1/en unknown
-
1997
- 1997-07-11 NO NO973231A patent/NO973231L/en not_active Application Discontinuation
- 1997-07-11 FI FI972970A patent/FI972970A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR19980701374A (en) | 1998-05-15 |
FI972970A0 (en) | 1997-07-11 |
NZ302117A (en) | 1999-10-28 |
EP0802908A4 (en) | 2001-04-11 |
BR9607097A (en) | 1997-11-11 |
HUP0102677A2 (en) | 2002-04-29 |
NO973231D0 (en) | 1997-07-11 |
EP0802908A1 (en) | 1997-10-29 |
AU709370B2 (en) | 1999-08-26 |
FI972970A (en) | 1997-09-11 |
WO1996021654A1 (en) | 1996-07-18 |
AU4770496A (en) | 1996-07-31 |
HUP0102677A3 (en) | 2002-09-30 |
CA2210322A1 (en) | 1996-07-18 |
NO973231L (en) | 1997-09-11 |
PL321292A1 (en) | 1997-11-24 |
JPH10512264A (en) | 1998-11-24 |
CZ219597A3 (en) | 1998-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9705296A (en) | Novel compounds. | |
IL125282A (en) | Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases | |
HUP0003351A3 (en) | 2-substituted 4,5-diaryl imidazoles, process for producing them, pharmaceutical compositions containing them and their use | |
BG101118A (en) | Therapeutical compounds | |
MY116478A (en) | Tri-substituted imidazoles having multiple therapeutic properties | |
PL317705A1 (en) | Pyrazole and pyrrole pyridines | |
UA39158C2 (en) | derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon | |
MY114014A (en) | Imidazole compounds, compositions and use | |
UA42747C2 (en) | Peptide derivatives, pharmaceutical composition and method for stimulating growth hormone releasing | |
MX9702932A (en) | L-ribofuranosyl nucleosides. | |
IL110031A0 (en) | Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them | |
BG100960A (en) | Dosage forms for controlled release of azitromycin | |
BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
MX9604378A (en) | Substituted quinoline-2-carboxylic acid amides, their preparation and their use as medicaments, as well as intermediate products thereof. | |
BG102726A (en) | Combined therapy for osteoporosis | |
MX9704030A (en) | 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof. | |
BG102250A (en) | The use of marigold-extracted glycosides for the treatment of psoriasis | |
EP0793660A4 (en) | 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof | |
MX9403088A (en) | Indole derivatives. | |
AU5892399A (en) | 1, 2, 4-triazole-3-thione compounds | |
MY128260A (en) | Cyclopentane-and-pentene-b-amino acids | |
GB9425730D0 (en) | Compounds | |
HUP9802634A3 (en) | Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia | |
BG105275A (en) | Tan-1057 derivatives | |
MX9704034A (en) | Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof. |